Eric Topol Profile picture
Sep 19, 2020 18 tweets 8 min read
We have the protocols. Now we know how there will very likely be an Emergency Use Approval (EUA) for a vaccine prior to November 3. The company and political motivations are fully aligned.
1. The criteria for an EUA is that it "may be effective"… Image
2. Nearly every day we hear from @pfizer's CEO @AlbertBourla that they will know if their vaccine is working by the end of October.
Only the Data and Safety Monitoring Board is reviewing the data at specific intervals, the interim analyses
So how will they (Pfizer) know that?
3. The 1st interim analysis for that trial is at 32 events, infections, which can and likely will be mild. The stopping rules as reviewed by @biosbenk @EmoryRollins are "aggressive" and "unusual" for the number of interim analyses (4) and Bayesian approach… Image
4. As presented in a poll, ≥ 26 infections in the placebo group at the 1st interim of 32 events would fulfill the stopping rule and support a claim of efficacy.
But the EUA only requires *"May be effective"* so even <26 placebo events could qualify
5. The DSMB reports to the sponsor. The trial data should not be unblinded unless it has been stopped (for futility, safety, or efficacy stopping rule) or completed. But it is easy to discern which group (vaccine or placebo) by the early adverse effects without unblinding.
6. Note the similarity in some symptoms for #COVID19 (which are the endpoint) and the early adverse effects of the vaccine (dose of 100 ug was used in Phase 3)… Image
7. So with or without fulfilling pre-specified efficacy criteria at the 1st interim look, which will occur within weeks, Pfizer can apply for an EUA with the low threshold of "may be effective"
(If Pfizer hits the stopping rule and doesn't stop the trial, that's another story)
8. The EUA criteria are so minimal that even the Phase 1/2 serology data (NEJM paper above) could fulfill "may be effective" and that would equate to the Russian vaccine approval and roll out.
9. There has only been one FDA EUA for a vaccine in history, which was for anthrax, and that didn't go well… by @sarahzhang Image
10. What if the FDA says NO, the data from 32 infections isn't enough? Clearly at that juncture there would be very limited data for the vaccine's safety.
The HHS can override that an issue the vaccine approval.
And we've already seen @HHSGov do that with FDA LDTs weeks ago.
11. The same issues apply for the @moderna_tx first interim analysis at 53 events, but a conventional O'Brien-Fleming stopping rule is being used and the 1° endpoint definition of infections is tighter
12. This is obviously a rush job—a race between companies with big political stakes. Once an EUA is issued for a vaccine, the whole landscape shifts. Safety issues could crop up later and engender mistrust. Ability to conduct placebo-controlled trials could be impaired.
13. These are the most important clinical trials of our lifetime. There's no need for this rush. We need to do them right; get the Phase 3 trials completed as planned at 150-160 events. That will only require waiting weeks, it'll give us more confidence about efficacy and safety
14. Just as pressure was applied to @pfizer @BioNTech_Group and @moderna_tx to release their protocols, we need to apply intense pressure to the companies, the FDA, and HHS to preempt any EUA until Phase 3 trials are *fully* completed.
15. Translation, TLDR:
We need a shot in the light, not in the dark.
A matter of weeks to nail the efficacy issue down is well worth the wait.
Zero tolerance for company or governmental shortcuts and related back door BS. Image
16. If there was any doubt about @HHSGov @SecAzar's plan to make sure there is an EUA for a vaccine before Nov 3 (see 10. above), then you can read this by @BySheilaKaplan…
17. No. Image

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Eric Topol

Eric Topol Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @EricTopol

Nov 28
A note of alarm from Ho lab about the immune escape features of XBB & BQ.1.1 variants…
—pseudovirus assay👇for bivalent booster has differed from live virus
—not seeing clinical sequelae (severe Covid in boosted) to correlate w/ lab findings to date
"Our findings indicate that BQ & XBB subvariants present serious threats to the efficacy of current COVID-19 vaccines, render inactive all authorized monoclonal antibodies, & may have gained dominance in the population because of their advantage in evading antibodies"
"The extent of the antigenic drift or shift measured herein is comparable to the antigenic leap made by the initial Omicron variant from its predecessors one year ago."
Read 4 tweets
Nov 15
Our prospective Paxlovid rebound study with controls preprint is posted
By symptoms: ~12% rebound (19% Pax vs 7% controls)
By positive testing: ~5% rebound (14% Pax vs 9% controls)
Much lower than many estimates… by @JayPandit @michaelmina_lab @ScrippsRTI
The event curves for Paxlovid treated compared with controls Image
Each participant did rapid antigen testing every other day through day 15, symptom surveys through day 17, and are being followed for 6 months Image
Read 4 tweets
Nov 10
Covid reinfections are bad for your health. Big @DeptVetAffairs study published @NatureMedicine today. #LongCovid…
by @zalaly and colleagues Image
Graphic of adverse outcomes by number of infections, a dose-response relationship Image
All-cause mortality, hospitalizations and adverse sequelae are increased by reinfection, not just in the acute phase but during 6 month follow up Image
Read 4 tweets
Nov 6
Important new preprint just posted from ⁦@zalaly⁩ and colleagues;
Paxlovid treatment for Covid associated with ~25% reduction of #LongCovid, beyond less death and hospitalization reduction…
Divergence of curves for reduction of #LongCovid
Breakdown of reduction by system and symptoms associated with Paxlovid vs controls
Read 6 tweets
Nov 2
A new, fourth assessment of the BA.5 bivalent booster showed augmented neutralizing antibody response to BA.5 compared to the original, but lacking a robust response to BQ.1.1, XBB and BA.2.75.2…
A 5th report on the bivalent booster vs BQ.1.1 today reinforces the high level of immune evasion of this variant, with minimal difference for the bivalent ->NAb compared with original (2022 below)… @BarouchLab (w/ pseudovirus assay)
Summary of the 5 bivalent booster reports…
Read 4 tweets
Oct 24
New on the bivalent BA.5 vaccine booster immune response in people
No better neutralizing antibody response to BA.5 than the original vaccine (WT)…
"The findings may be indicative of immunological imprinting"
Bottom line: Until more data are available, regard the bivalent booster as equivalent to a booster which augments and broadens immunity, without specific anti-BA.5 properties.
In August, I previously expressed concern that this would be the case with the BA.5 bivalent booster…
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!